BioSpace News Archive

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) (“Rexahn”) announced today that the merger transaction between Rexahn and Ocuphire Pharma, Inc. is expected to be effective shortly after 4:00 pm (EST) today, Thursday, November 5, 2020

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the Pre-IDE meeting with the U.S. Food and Drug Administration regarding the VenoValve U.S. pivotal trial has been set for December 22, 2020.

Magnostics is leading a consortium of University and National Researchers to develop and launch Viral RNA Extraction Kits for detection of COVID-19.

Chimerix, a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced that Mike Sherman, Chief Executive Officer, will present a corporate overview and program update at the Credit Suisse 29th Annual Healthcare Conference on Thursday, November 12, 2020 at 4:15 p.m. ET.

Strengthened Formulary Access for Xtampza® ER, Including Exclusive National Medicare Part D Win

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Otis Brawley, M.D., has been appointed to PDS Biotech’s Board of Directors.

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the third quarter ended September 30, 2020.

Neovasc, Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, reported financial results for the third quarter ended September 30, 2020.

Editas Medicine, Inc., a leading genome editing company, reported business highlights and financial results for the third quarter of 2020.

Dosing with SRP-9001 commercial-process material to proceed followingdiscussions with U.S. FDA